Cegedim Dendrite taps O'Rourke as consultant

Share this article:
Peg O'Rourke
Peg O'Rourke

Sales, marketing and compliance solutions consulting firm Cegedim Dendrite has hired one of the nation's foremost FDA regulations experts.

Margaret “Peg” O'Rourke, who spent a 35-year career at the FDA until her retirement earlier this year, has been named senior regulatory consultant for Cegedim Dendrite.

For the past 20 years, O'Rourke was responsible for enforcing the Prescription Drug Marketing Act (PDMA) amendments to the Federal Food, Drug, and Cosmetic Act.

PDMA amendments affect the distribution of prescription drug samples and the integrity of the national drug distribution system, including counterfeiting and the importation of prescription drugs into the US.

“Essentially I'm going to be doing the same thing for Cegedim Dendrite that I was doing for FDA, in the sense that I will be trying to assist the pharmaceutical industry in meeting the FDA regulations and statutes,” O'Rourke told MM&M. “It's a little different side of the coin but not totally. The whole point is to help the pharmaceutical manufacturers comply with the FDA rules and regulations.”

As part of Cegedim Dendrite O'Rourke will be responsible for third-party audits; sales force and home office training; mock FDA audits, general consultation and expert guidance regarding PDMA compliance issues.

Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...